Please assess the completion status of the following clinical trial:

Trial Title: Adhesion Performance Study of Lidocaine Topical System 1.8% Compared to Generic Lidocaine Patch 5% in Healthy, Adult, Human Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Must be healthy based on by medical history, laboratory work, ECG, and physical exam with BMI range between 18.00 and 30.00 kg/m2 inclusive.~* Be at least 18 years of age~* If childbearing potential, use of acceptable form of birth control~* In the case of females of childbearing potential, have a negative serum pregnancy test~Key Exclusion Criteria:~* Allergy or known hypersensitivity to lidocaine, amide-type local anesthetics, or any component of the product formulation~* Any major medical illness 3 months prior or any significant history or ongoing chronic medical illness~* Subjects with conditions that might affect application of the product or its adhesive properties (including psoriasis, eczema, atopic dermatitis, damaged or irritated epidermal layer, and excessive hair or oil on the skin)~* History of addiction, abuse, and misuse of any drug~* Use of local anesthetics of antiarrhythmic drugs (such as tocainide or mexiletine) within 14 days prior to product application

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Lidocaine Patch (Sequence T1T2) (Type: EXPERIMENTAL): Subjects receive both lidocaine topical system 1.8% and the generic lidocaine patch 5%. The sequence in which they receive the lidocaine products is determined by random assignment. For subjects in Arm 1, lidocaine 1.8% topical systems are applied in Period 1, and the generic lidocaine 5% patches are applied in Period 2.
- Lidocaine Patch (Sequence T2T1) (Type: EXPERIMENTAL): Subjects receive both lidocaine topical system 1.8% and the generic lidocaine patch 5%. The sequence in which they receive the lidocaine products is determined by random assignment. For subjects in Arm 2, generic lidocaine 5% patches are applied in Period 1, and the lidocaine 1.8% topical systems are applied in Period 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).